Cixutumumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Cixutumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1 receptor
Identifiers
CAS Number 947687-12-9 N
ATC code none
UNII 2285XW22DR YesY
KEGG D09328 YesY
Chemical data
Formula C6500H10052N1724O2036S44
Molecular mass 146.3 kg/mol
 NYesY (what is this?)  (verify)

Cixutumumab is a monoclonal antibody for the treatment of solid tumors.[1][2]

This drug was developed by ImClone Systems Inc. under the name IMC-A12.

It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.[3]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ [1] National Cancer InstituteTemplate:Http://www.cancer.gov/drugdictionary/?CdrID=561575


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Cixutumumab&oldid=722782099"